GenScript Biotech’s Legend Biotech Terminates LB1901 CAR-T Phase I Trial
Hong Kong-based GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary Legend Biotech Corporation (NASDAQ:...
Cancer
I-Mab and MorphoSys License Drugs to HIBio in Global Oncology Deal
China-based I-Mab (NASDAQ: IMAB) detailed a licensing and equity investment deal between its German partner...
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:...
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...
Hansoh Pharmaceutical’s Generic Ibrance Approved by NMPA
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received market approval...
InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies
Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...
Akeso Biopharma’s Cadonilimab Achieves National Delivery in China
China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
NHC Releases Technical Guidelines for Drug Clinical Evaluation
The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...
Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...
Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection
Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...
BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study
BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer
China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...
AnchorDx and West China Hospital Collaborate on Lung Cancer Early Diagnosis
Guangzhou-based AnchorDx and West China Hospital of Sichuan University have entered into a transfer agreement...